Zimbabwe has rejected a major US health deal worth $367m (£272m) spanning five years due to Washington's request for confidential biological samples.
The decision was revealed following a government memo dated December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the agreement was "unbalanced".
An official representative later clarified that the US was requesting genetic material for research and commercial gain while was unwilling to guarantee the benefits from future medical innovations.
"We must now begin the challenging and unfortunate task of ending our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had furnished more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged further negotiations to find a agreement agreeable to both sides so the country's critical HIV treatment initiative can continue.
Broader Implications
This development comes after a similar case in neighbouring Kenya, where a court blocked a related deal with the US after concerns were filed about the safety of Kenyans' health data.
Since returning to the presidency recently, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
USAID had administered aid for the American government, but Trump stated its expenditure was "inefficient" and his government was pursuing government-to-government agreements to enhance transparency and responsibility.
As per statements, Sixteen nations in Africa have to date signed these new agreements, representing more than $18.3bn in committed funds.
Details of the Rejected Agreement
This assistance for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this cooperation might have yielded significant benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently on HIV treatment through US-supported programmes," Tremont said.
However, government spokesperson Nick Mangwana said the proposed deal was "unfair".
"The proposal required Zimbabwe to provide its genetic material and health information for a long time, without any equivalent promise of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that shared data," his statement read.
"Put simply, our country would provide the basic resources for medical research with no assurance that the resulting innovations would be accessible to our people should a future health crisis arise."
Sovereignty and International Frameworks
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were upending structures previously established via the international organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework designed to deal with potential pandemics.
"This system is designed to ensure that when a country contributes its samples, the benefits – such as medicines and cures – are shared equitably, not commercialised solely by those with the funds to develop them."
Zimbabwe's reservations regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We welcome further dialogue with our American counterparts on how subsequent co-operation might be designed in a manner that honours the sovereignty and dignity of both nations."
Medical Community Response
A leading public health body expressed it understood the government's concerns, but recommended that talks should continue given that a large portion of the nation's Aids initiatives depended on external financing.
"Where specific concerns exist, such as those relating to information security or implementation frameworks, these can often be addressed through technical clarification and mutually agreed protections," the group commented.
The halted deal underscores the ongoing tensions between accepting crucial foreign assistance and safeguarding a country's data in an increasingly data-driven world.